Literature DB >> 1869465

Sensori-neural hearing loss in patients treated with irradiation for nasopharyngeal carcinoma.

C Grau1, K Møller, M Overgaard, J Overgaard, O Elbrønd.   

Abstract

The present investigation has been carried out to evaluate the sensitivity of the inner ear to irradiation. Cochlear function was tested in a cohort of 22 patients before and 7-84 months after receiving external irradiation for nasopharyngeal carcinoma. The pre-irradiation sensori-neural hearing threshold at 500, 1000, 2000, and 4000 Hz was used as a baseline for the individual patient, and the observed sensori-neural hearing loss (SNHL) was calculated as the difference between pre- and post-irradiation values. The pre-irradiation hearing level or patient age was not correlated with the actual SNHL. In contrast, there was a significant correlation between the total radiation dose to the inner ear and the observed hearing impairment. SNHL was most pronounced in the high frequencies, with values up to 35 dB (4000 Hz) and 25 dB (2000 Hz) in some patients. The latent period for the complication appeared to be 12 months or more. The deleterious effect of irradiation on the hearing should be kept in mind both in treatment planning and in the follow-up after radiotherapy.

Entities:  

Mesh:

Year:  1991        PMID: 1869465     DOI: 10.1016/0360-3016(91)90692-w

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Ototoxicity after radiotherapy of head-and-neck cancer: the perils of retrospective dose-response estimations: in regard to Bhandare et al. (Int J Radiat Oncol Biol Phys 2007;67:469-479).

Authors:  Charlie Pan; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-01       Impact factor: 7.038

2.  Radiotherapy for head and neck cancer.

Authors:  Shyh-An Yeh
Journal:  Semin Plast Surg       Date:  2010-05       Impact factor: 2.314

Review 3.  Organ-sparing radiation therapy for head and neck cancer.

Authors:  XiaoShen Wang; ChaoSu Hu; Avraham Eisbruch
Journal:  Nat Rev Clin Oncol       Date:  2011-07-26       Impact factor: 66.675

4.  Parotid carcinoma: Current diagnostic workup and treatment.

Authors:  Vincent L M Vander Poorten; Francis Marchal; Sandra Nuyts; Paul M J Clement
Journal:  Indian J Surg Oncol       Date:  2010-11-21

5.  Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy.

Authors:  Susan Cheraghi; Parsa Nikoofar; Pedram Fadavi; Mohsen Bakhshandeh; Samideh Khoie; Elahe Jazayeri Gharehbagh; Saeid Farahani; Alireza Mohebbi; Maryam Vasheghani; Mahkameh Zare; Alireza Nikoofar; Seied Rabi Mehdi Mahdavi
Journal:  Med Oncol       Date:  2015-06-13       Impact factor: 3.064

6.  Effects of irradiation on the rat middle ear mucosa. A scanning electron microscopic study.

Authors:  W Y Chao; H W Leung
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

7.  Cisplatin and cranial irradiation-related hearing loss in children.

Authors:  Rajasekharan Warrier; Aman Chauhan; Murali Davluri; Sonya L Tedesco; Joseph Nadell; Randall Craver
Journal:  Ochsner J       Date:  2012

8.  Late effects of radiotherapy on hearing.

Authors:  L J Schot; F J Hilgers; R B Keus; P F Schouwenburg; W A Dreschler
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

9.  Definition of an Normal Tissue Complication Probability Model for the Inner Ear in Definitive Radiochemotherapy of Nasopharynx Carcinoma.

Authors:  Leonie Peuker; Daniel Rolf; Michael Oertel; Alexander Peuker; Sergiu Scobioala; Dominik Hering; Claudia Rudack; Uwe Haverkamp; Hans Theodor Eich
Journal:  Cancers (Basel)       Date:  2022-07-14       Impact factor: 6.575

10.  Dose-volume factors associated with ear disorders following intensity modulated radiotherapy in nasopharyngeal carcinoma.

Authors:  Ji-Jin Yao; Guan-Qun Zhou; Li Lin; Wang-Jian Zhang; Ying-Lin Peng; Lei Chen; Ling-Long Tang; Yan-Ping Mao; Jun Ma; Ying Sun
Journal:  Sci Rep       Date:  2015-09-01       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.